Since the beginning of time, genetics has played a huge role in life. Your genetic makeup can determine your height, skin color, and even which diseases you are susceptible too. For many years, we had no control over genetics, but in the past few decades, doctors and scientist around the globe have started developing genetic therapies. Many doctors believe that genetic therapy could solve issues like cancer, diabetes, and hunger. There are several major companies working on genetic therapies in the United States, and Seattle Genetics is one of the top companies.
Seattle Genetics was founded several years ago, with Clay Siegall at the head of the company. They have been developing treatments for Lymphoma and other forms of cancer for several years, and they are starting to turn the corner towards profitability. Recently, Clay Siegall held a meeting with major stakeholders to discuss the results of the last quarter.
Clay Siegall is extremely pleased with the faith that investors have placed in his company. He believes that this faith is starting to pay-off. Seattle Genetics’ main product is ADCERTIS. Clay believes that ADCERTIS is well on its way to becoming a major franchise, and will help establish the company as a major oncology firm. ADCERTIS is permanently changing the way that CD30-expressing lymphoma is treated.
Seattle Genetics is also working on SGN-CD33A, another major drug. This drug has made it through several major rounds of testing, and it is now entering trials. SGN-CD33A shows hope when it comes to helping AML patients live longer lives.
Seattle has many other treatments in the works. These treatments are aimed at everything from breast cancer to urothelial cancer. Clay is highly involved in all of these treatment methods, and he loves watching these potential cures grow.
Clay Siegall was happy to report an increase in profits this year. The company earned around $100 million in the second quarter of this year. That is a significant increase for the company.
Clay Siegall believes that Seattle Genetics is developing the cures of the future. He believes that investors should remain encouraged when it comes to the future of genetic therapy.